<DOC>
	<DOCNO>NCT02156388</DOCNO>
	<brief_summary>This study design access safety , tolerance Pharmacokinetic/Pharmacodynamic ( PK/PD ) single subcutaneous ( SC ) injection GW003 patient metastatic tumor .</brief_summary>
	<brief_title>Safety Pharmacokinetic ( PK ) Study GW003 Metastatic Tumors</brief_title>
	<detailed_description>So far , granulocyte colony stimulate factor ( G-CSF ) still currently effective security therapy drug neutropenia cause cancer chemotherapy . At present , widely use G-CSF product short-acting G-CSF product China . However , exist shortcoming short-acting G-CSF , short half-life , continuous monitoring patient 's blood neutrophil count . Nowadays , long-acting G-CSF product , Neulasta® , become mainstream foreign G-CSF market superiority long half-life absence monitoring patient 's blood neutrophil count . The new drug Recombinant ( Expressed Pichia pastoris ) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor ( I ) Fusion Protein ( GW003 ) long-acting G-CSF.Preclinical study show GW003 accelerate neutrophil recovery shorten duration neutropenia symptom , also reduce extent , therefore minimize likelihood serious infection , reflect well efficacy long half-life . Phase I perform two part , Ia Ib . Ia sequential dose escalation observe dose-limiting toxicity ( DLT ) Maximum Tolerated Dose GW003 give subcutaneously patient without receive chemotherapy,6 dose cohort ( 50、150、300、400、500 600μg/kg ) 2-3 subject 50、150μg/kg cohort 3-6 subjects（depend Dose-limiting toxicity） 300、400、500 600μg/kg cohort , evaluate safety pharmacokinetics prior Ⅰb . Ib propose two arm ( 150 300μg/kg；n=6-8/arm ) , determine whether continue increase dose arm base safety efficacy assessment . Subjects need receive two cycle treatment AT chemotherapy . In cycle 1 , subject receive AT chemotherapy ; cycle 2 , subject administer subcutaneously GW003 24 hour chemotherapy drug .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients pathologically and/or cytologicallyconfirmed malignant tumor ( phase Ia ) 2 . Breastcancer NSCLC patient suitable chemotherapy regimen receive docetaxel plus adriamycin could finish twocycles adjuvant chemotherapy schedule 3 . 18 year 65years 4 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 living least 6 month 5 . No main organ dysfunction , adequate cardiac , hepatic , renal bone marrow function 6 . Adequate hematologic function ( value center laboratory standard ) ; white blood cell count ( WBC ) ≥4.0×109/L neutrophil count ( ANC ) ≥1.5×109/L ; platelet count ( PLT ) ≥100×109/L ; hemoglobin ( HGB ) ≥lOO g/L . 7 . Adequate hepatic renal function ( value center laboratory standard ) : 8 . Women childbearing age need pregnancy test Prior receive therapy agree use effective contraception throughout study 9 . Subjects , willing follow study protocol provide write informed consent voluntarily , understand purpose procedure could follow requirement study 1 . History cardiopathy sign symptom 2 . History bone marrow transplant and/or stem cell transplant 3 . Patients acute infection , systemic antiinfection treatment within 72 hour study 4 . Prior participated drug therapy , radiotherapy surgery clinical trial within 4 week 5 . Prior use recombinant human GCSF ( rhGCSF ) 、PEGrhGCSF erythropoietin within 4 week study 6 . Patients history primary myeloid malignancy myelodysplasia 7 . Known hypersensitivity test drug , rhGCSF biologicals 8 . Pregnant female nursing mother 9 . Known HIV positive active hepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>